ProCE Banner Activity

Phase I Study of Cevostamab in Patients With Heavily Pretreated R/R MM: Dosing Schedule, Updated Safety and Efficacy Results

Slideset Download
Conference Coverage
In this phase I trial update, cevostamab continued to demonstrate clinical activity and a safety profile that supports additional development; double step-up dosing in cycle 1 appeared to mitigate some risk of cytokine release syndrome.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation